Presepsin: A promising novel biomarker for the detection of sepsis

Yıl 2021, Cilt: 8 Sayı: 3, 553 - 557, 30.09.2021

Meltem Malkoç , Birgül Kural

https://doi.org/10.34087/cbusbed.887818

Cited By: 3

Öz

Sepsis, also defined as systemic inflammatory response syndrome, is defined as life-threatening multi-organ dysfunction. Early diagnosis in severe bacterial infections such as sepsis, is very important for the treatment and control of infectious diseases. However, the basic problem in recognizing bacterial infections is that the signs and symptoms often overlap with the clinical symptom of other inflammatory disorders. Although microbiological, biochemical and molecular methods have been widely used in the diagnosis of infections, they have some limitations in terms of sensitivity and specificity. Therefore, a gold standard indicator has not been revealed yet. The proposed biomarkers should be determined by cost-effective, fast, simple, reliable, specific and sensitive methods.
Presepsin is a new protein also known as soluble cluster of differentiation 14 (sCD14-ST) subtype. It regulates the cellular and humoral immune system by directly interacting with T and B cells. It increases in response to bacterial infections and decreases after antibiotic therapy. Therefore, it is considered as an indicator of activation of the immune cell response against an invading pathogen. It is also suggested that it may be an early biomarker for sepsis.
Presepsin has gained an important place in recent studies due to its stability in the general circulation and being a candidate biomarker of the first stage of systemic infection. The number of research articles and reviews about presepsin is increasing day by day in the literature. The purpose of this review is to evaluate the place and importance of presepsin measurement in sepsis, considering other sepsis biomarkers, which will provide great benefits to clinicians.

Anahtar Kelimeler

Sepsis, Presepsin, sCD14-ST, Biyomarker, Infection

Presepsin: Sepsis tespiti için umut verici yeni bir biyobelirteç

Öz

Sistemik inflamatuar yanıt sendromu (SİYS) olarak da tanımlanan sepsis, hayatı tehdit eder boyutta seyreden çoklu organ fonksiyon bozukluğu olarak tanımlanmaktadır. Sepsis gibi ciddi bakteriyel enfeksiyonlarda erken teşhis, bulaşıcı hastalıkların tedavisi ve kontrolü için oldukça önem arz etmektedir. Ancak, bakteriyel enfeksiyonların tanınmasındaki ana problem, belirti ve semptomların klinik görünümünün sıklıkla diğer enflamatuvar bozukluklarla örtüşmesidir. Enfeksiyonların teşhisinde mikrobiyolojik, biyokimyasal ve moleküler yöntemler yaygın kullanılmasına rağmen, duyarlılık ve özgüllük açısından bazı sınırlamaları mevcuttur. Bu nedenle henüz altın standart bir belirteç ortaya konulamamıştır. Önerilen biyobelirteçlerin, uygun maliyetli, hızlı, basit, güvenilir, spesifik ve hassas yöntemlerle belirlenebilmesi gerekmektedir.
Presepsin, çözünür farklılaşma kümesi 14 (SCD14-ST) alt tipi olarak da bilinen bir proteindir. T ve B hücreleri ile direkt etkileşime girerek hücresel ve humoral bağışıklık sistemini düzenler. Bakteriyel enfeksiyonlara yanıt olarak artmakta ve antibiyotik tedavisinden sonra azalmaktadır. Bu nedenle de, istilacı bir patojene karşı immün hücre yanıtının aktivasyonunun bir göstergesi olarak düşünülmektedir. Ayrıca sepsis için erken bir biyobelirteç olabileceği ileri sürülmektedir.
Presepsin, genel dolaşımda kararlı olması ve sistemik enfeksiyonun ilk aşamasının aday bir biyobelirteç olması nedeniyle son yıllardaki çalışmalarda önemli yer edinmiştir. Literatürde presepsin hakkında araştırma makalesi ve derleme sayısı her geçen gün artmaktadır. Bu derlemenin amacı, klinisyenlere rehber olması açısından büyük yararlar sağlayacak presepsin ölçümünün sepsisdeki yeri ve önemi diğer sepsis biyobelirteçleri göz önüne alınarak değerlendirmektir.

Anahtar Kelimeler

sepsis, presepsin, sCD14-ST, Biyobelirteç, Enfeksiyon

Kaynakça

• Dkhil, M.A, Al-Quraishy, S, Moneim, A.E.A, Ziziphus spina-christi leaf extract pretreatment inhibits liver and spleen injury in a mouse model of sepsis via anti-oxidant and anti-inflammatory effects, Inflammopharmacology, 2018, 26 (3), 779-791.
• Wu, J, Hu, L, Zhang, G, Wu, F, He, T, Accuracy of presepsin in sepsis diagnosis: a systematic review and meta-analysis, PLoS One, 2015, 10 (7), e0133057.
• Kibe, S, Adams, K, Barlow, G, Diagnostic and prognostic biomarkers of sepsis in critical care, Journal of antimicrobial chemotherapy 2011, 66 (suppl_2), ii33-ii40.
• Sönmezer, M.Ç, Tülek, N, Bakteriyel Infeksiyonlarda ve Sepsiste iyobelirteçler/Biomarkers in Bacterial Infections and Sepsis, Klimik Dergisi, 2015, 28 (3), 96.
• Aliu-Bejta, A, Atelj, A, Kurshumliu, M, Dreshaj, S, Baršić B, Presepsin values as markers of severity of sepsis, International Journal of Infectious Diseases, 2020, 95, 1-7.
• Pierrakos, C, Velissaris, D, Bisdorff, M, Marshall, J.C, Vincent, J.L, Biomarkers of sepsis: time for a reappraisal,Critical Care ,2020, 24, 1-15.
• Grondman, I, Pirvu, A, Riza, A, Ioana, M, Netea, M.G, Biomarkers of inflammation and the etiology of sepsis, Biochemical Society Transactions, 2020, 48 (1), 1-14.
• Henriquez-Camacho, C, Losa, J, Biomarkers for sepsis, BioMed research international, 2014,2014.
• Özdemir, A.A, Diagnostıc Reliabiiıty Of Crp And Procalcitonin in Early-Onset Neonatal Sepsis And The impact Of Fetal Dıstress (Running T itle: The reliability of CRP and procalcitonin), Int J Basic Clin Med, 2016, 4(3), 118-25.
• Wu CC, Lan HM, Han ST, Chaou CH, Yeh CF, Liu SH, Chen KF. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis, Annals of intensive care, 2017, 7 (1), 1-16.
• Marshall, J.C, Reinhart, K, Biomarkers of sepsis, Critical care medicine, 2009, 37 (7), 2290-2298.
• Szilágyi, B, Fejes, Z, Pócsi, M, Kappelmayer, J, Nagy, Jr B,Role of sepsis modulated circulating microRNAs, Ejifcc, 2019, 30 (2), 128.
• Kundakci, A, Pirat, A, Toll Benzeri Reseptörler/Toll-Like Receptors, Türk Yogun Bakim Dergisi, 2012, 10(2), 63.
• Memar, M.Y, Baghi, H.B, Presepsin: a promising biomarker for the detection of bacterial infections, Biomedicine & Pharmacotherapy, 2019,111, 649-656.
• Chenevier-Gobeaux, C, Borderie, D, Weiss, N, Mallet-Coste, T, Claessens, Y.E, Presepsin (sCD14-ST), an innate immune response marker in sepsis, Clinica chimica acta 2015,450, 97-103.
• Zou, Q, Wen, W, Zhang, X.C, Presepsin as a novel sepsis biomarker,World journal of emergency medicine, 2014, 5 (1), 16.
• Nores, J.E.R, Bensussan, A, Vita, N, Stelter, F, Arias, M.A, Jones, M, Labéta, M.O, Soluble CD14 acts as a negative regulator of human T cell activation and function, European journal of immunology, 1999, 29 (1), 265-276.
• Ackland, G.L, Prowle, J.R, Presepsin: solving a soluble (CD14) problem in sepsis? Intensive Care Medicine, 2015, 41, 351–353.
• Zhao, J, Tan, Y, Wang, L, Shi, Y, Discriminatory ability and prognostic evaluation of presepsin for sepsis-related acute respiratory distress syndrome, Scientific Reports, 2020, 10(1), 1-10.
• Drăgoescu, A.N, Pădureanu, V, Stănculescu, A.D, Chiuțu, L.C, Florescu, D.N, Gheonea, I.A, Drăgoescu, O.P, Presepsin as a Potential Prognostic Marker for Sepsis According to Actual Practice Guidelines, Journal of Personalized Medicine, 2021,11(1), 2.
• Vodnik, T, Kaljevic, G, Tadic, T, Majkic-Singh, N, Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis, Clin. Clinical chemistry and Laboratory Medicine, 2013, 51 (10) 2053–2062.
• Zhang, J, Hu, Z.D, Song, J, Shao, J, Diagnostic value of presepsin for sepsis: A systematic review and meta-analysis, Medicine, 2015, 94, e2158.
• Rogić, D, Juroš, G. F, Petrik, J, Vrančić, A. L, Advances and pitfalls in using laboratory biomarkers for the diagnosis and management of sepsis, Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2017, 28(2), 114.
• Ackland, Gareth L, John, R, Prowle. Presepsin: solving a soluble (CD14) problem in sepsis? Intensive Care Med, 2015, 41, 351–353.
• Endo, S, Suzuki, Y, Takahashi, G, Shozushima, T, Ishikura, H, Murai, A, Okamura, Y, Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study, Journal of Iinfection and Chemotherapy, 2012,18 (6), 891-897.
• Godnic, M, Stubjar, D, Skvarc, M, Jukic, T,Diagnostic and prognostic value of sCD14-ST-presepsin for patients admitted to hospital intensive care unit (ICU), Wiener klinische Wochenschrift, 2015, 127 (13), 521-527.
• Bellos, I, Fitrou, G, Pergialiotis, V, Thomakos, N, Perrea, D.N, Daskalakis, G, The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis, European journal of pediatrics, 2018, 177 (5), 625-632.
• Galliera, E, Massaccesi, L, De, Vecchi, E, Banfi, G, Romanelli, M.M.C, Clinical application of presepsin as diagnostic biomarker of infection: overview and updates, Clinical Chemistry and Laboratory Medicine (CCLM), 2019, 58 (1), 11-17.
• Ali, F.T, Ali, M.A, Elnakeeb, M.M, Bendary, H.N, Presepsin is an early monitoring biomarker for predicting clinical outcome in patients with sepsis, Clinica Chimica Acta, 2016, 460, 93-101.
• Fukada, A, Kitagawa, Y, Matsuoka, M, Sakai, J, Imai, K, Tarumoto, N, Maeda, T, Presepsin as a predictive biomarker of severity in Covid-19: a case series, Journal of Medical Virology, 2020, 93 (1), 99-101.
• Shirakawa, K, Naitou, K, Hirose, J, Takahashi, T, Furusako, S, Presepsin (sCD14-ST): development and evaluation of one-step ELİSA with a new standard that is similar to the form of presepsin in septic patients, Clinical Chemistry and Laboratory Medicine (CCLM), 2011,49 (5), 937-939.
• Okamura, Y, Yokoi, H, Development of a point-of-care assay system for measurement of presepsin (sCD14-ST), Clinica Chimica Acta, 2011, 412 (23-24), 2157-2161.